Results of a recent study show that patients treated with Juvéderm Voluma XC are highly satisfied with their results.
Allergan’s Juvéderm Voluma XC is a hyaluronic acid filler used for correcting age-related midface volume deficit (MVD). The study, headed by Julius Few, M.D., clinical professor of surgery in the Division of Plastic Surgery at the University of Chicago Pritzker School of Medicine, sought to get patients’ input on the filler’s effectiveness.
A total of 235 patients with moderate to severe age-related MVD participated in the study. During quarterly follow-up visits over two years following treatment with Juvéderm Voluma XC, the patients rated treatment outcomes on the Global Aesthetic Improvement Scale (GAIS), overall satisfaction with facial appearance, satisfaction with midfacial regions, achievement of treatment goal, look and feel of the midface (LAFM) and self-perception of age (SPA). Patients recorded treatment-site responses in 30-day diaries.
The mean injection volume (both sides of the face) for initial and touch-up treatments combined was 6.68 mL. The mean injection volume for initial treatment was 5.09 mL and 1.93 mL for touch-up treatment. Mean injection volumes for initial and touch-up treatments combined for the zygomaticomalar region, anteromedial cheek and submalar region were 2.39 mL, 2.12 mL and 2.42 mL, respectively. Both subcutaneous and supraperiosteal injection planes were used for 67.3%, 54.9% and 24.5% of injections in the zygomaticomalar region, anteromedial cheek and submalar region, respectively. The remainder of injections used only one of the injection planes.
Study Findings
The authors found that at six months and two years after treatment, 92.8% and 79% of patients, respectively, rated their cheek volume as improved or much improved on the GAIS. Improvement in satisfaction with facial appearance was noted by 89.8% of patients at six months and 75.8% at two years. Increased satisfaction with outer and lower cheek areas and cheek bone projection and clinically significant improvements in LAFM were noted through month 24. Treatment goals were achieved by 67.8% of patients at six months and 49% at two years.
Related: Allergan survey: Face wins
Patients reported looking five years younger at six months and three years younger at two years, on average. The most common treatment-site responses were mostly mild to moderate tenderness, swelling, firmness and lumps or bumps that lasted about two weeks.
“The study is one of the first of its kind to focus on patients’ perspective of satisfaction for a non-invasive facial procedure,” Dr. Few tells Cosmetic Surgery Times. “The results show that patients actually rated their feeling of improvement higher than the study’s evaluators did.”
Dr. Few serves on Allergan’s advisory board.
The study appears in Aesthetic Surgery Journal.
